- Report
- January 2024
- 120 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- November 2021
- 802 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- February 2023
- 280 Pages
Global
From €3394EUR$3,570USD£2,851GBP
- Report
- July 2021
- 243 Pages
Global
From €3529EUR$3,712USD£2,965GBP
- Book
- March 2022
- 896 Pages
- Book
- January 2009
- 416 Pages
The Recombinant DNA market is a subset of the genomics industry, which focuses on the manipulation of genetic material to create new products. It involves the use of recombinant DNA technology to modify existing DNA sequences, or to create new ones. This technology is used to produce a variety of products, such as therapeutic proteins, vaccines, and diagnostics. It is also used in research and development, as well as in the production of genetically modified organisms.
The Recombinant DNA market is driven by the increasing demand for biopharmaceuticals, as well as the need for more efficient and cost-effective production of these products. Additionally, the development of new technologies, such as gene editing, is expected to further drive the market.
Some of the major companies in the Recombinant DNA market include Amgen, Novartis, Merck, Pfizer, and Johnson & Johnson. Other notable players include AbbVie, AstraZeneca, Bristol-Myers Squibb, and GlaxoSmithKline. Show Less Read more
